With the success of our last picnic: we have planned anther one! Please join us on the 18th of September in Cambridge for another evening of socialising with your fellow imaging scientists. Please see details and register here: https://t.co/fBu3dVEjML🥳🍻🌄
🚀 Trailblazers in UK PET: Meet @SelenaSephton! 🔬
We're excited to kick off our Trailblazers in UK PET series by introducing you to members of our editorial board! As a vital member of our editorial board, Selena brings a wealth of experience and passion to the @UKPETChemistry
We discuss the potential miRNA have as PET radiotracers and PET targets. Several approaches are considered utilising targeting with small molecules or direct radiolabelling of ASOs. @MICLCambridge https://t.co/vkiFEZSCWO
We discuss the potential miRNA have as PET radiotracers and PET targets. Several approaches are considered utilising targeting with small molecules or direct radiolabelling of ASOs. @MICLCambridge https://t.co/vkiFEZSCWO
👉 Join us for an enlightening presentation on "The Pathway to DJ-1 Based Precision Therapies for Parkinson’s by Maintaining Cellular Redox Homeostasis." by Gergely Toth together with Darwin Entrepreneurs Club.
⭐️⭐️ Abstract ⭐️⭐️
This talk will explore the critical role of DJ-1 protein in cellular survival, its connection to redox homeostasis, and the implications for aging-related diseases. Discover how oxidative stress leads to DJ-1 dysfunction, contributing to both familial and sporadic Parkinson’s disease. The session will also cover innovative therapeutic strategies targeting DJ-1, including pharmacological chaperones and enzyme replacement therapies, aimed at combating Parkinson’s. Additionally, learn about the potential of using various oxidized states of DJ-1 as biomarkers for Parkinson’s disease, assessed through novel ELISA techniques. This presentation will be extremely insightful for those interested in the latest advancements in neurodegenerative disease research and therapy.
⭐️⭐️About Gergely⭐️⭐️
Gergely Tóth (PhD, MBA) is the CEO, CSO and founder of Cantabio Pharmaceuticals, Inc. (USA), a preclinical stage biopharmaceutical company focusing on developing novel disease modifying precision therapeutics and diagnostics for neurodegenerative diseases. In addition, Dr. Tóth is an Honorary Associate Professor at the School of Pharmacy at University College London lecturing to graduate students on topics as the business of biotech and bioentrepreneurship.
Look Forward to Seeing you There! 😁
Our latest work with @Sanford_Lab & @Merck introduces #HighThroughput#Radiochemistry, and reduces the time for identifying & optimizing radiolabeling from weeks/months to just a few days. Funded by @NIBIBgov & out in @J_A_C_S, we're excited to share this: https://t.co/1iFRiF11DL
It was amazing having Florence Pugh in our lab at @Cambridge_Uni, speaking about dementia and our research work - big thanks to her for being such a great ambassador for @racingdementia!
Her full interview: https://t.co/uw6V4TLuRI
So great to have been able to do this in person again! A successful #HDopenday took place yesterday organised by the research team. A line up of fantastic talks, stations and of course questions. @zanna_voysey @MiriamSchaepers
📢 ...when everything falls into place:
Launch of #EMIM2024 programme, enjoy browsing through sessions & abstracts via https://t.co/yWOEFJ5po1.
Notifications to presenters went out yesterday 📬 and a big thanks to all of you who contributed!
📍12-15 March, Porto 🇵🇹
First Neurotalk of the academic year! Join us at the Cambridge tap on Tuesday the 10th of October from 7pm. We will hear from three exciting speakers all about emotions! 🎭
This event is open to anyone and will double as a welcome party to new and old friends of CamBrain alike!